Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color Jun. 07, 2025 6:30 PM ET Regeneron Pharmaceuticals ...

Unfortunately, treating atopic dermatitis on the hands and feet has historically been difficult and there have been no Phase 3 trials evaluating a biologic in this population of patients,” said ...

Children with moderate/more extensive atopic dermatitis treated with ruxolitinib cream achieved significant disease control ...

REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.

Regeneron Pharmaceuticals and Sanofi have announced promising outcomes from the open-label Phase IV DISCOVER trial of Dupixent (dupilumab) in treating moderate-to-severe atopic dermatitis (AD) in ...

Four out of 10 eczema patients struggle with sleep, and they may not volunteer that information unless you ask.

Atopic dermatitis is a chronic skin condition driven by type 2 inflammation, often presenting with more pronounced symptoms and skin lesions in individuals with skin of color. Dupixent was ...

If you're looking to put cash into two fantastic biotech stocks that Wall Street seems particularly bullish on, there's one ...

Moderate-to-Severe Atopic Dermatitis: Optimizing Care Across Specialties This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail ...

Please provide your email address to receive an email when new articles are posted on . Patients with hand and foot atopic dermatitis (HFAD) endure significant discomfort, impaired quality of life ...

Shares of Regeneron ticked up 0.2% Friday, while Sanofi shares listed in the U.S. rose 1.1%. The companies' stocks are up about 19% and 16%, respectively, since the start of the year.